For the millions of adults living with serious mood or psychotic disorders, dementia risk is already elevated well above the general population — and treatment options that might address both conditions simultaneously have been elusive. New evidence from a large U.S. veterans cohort suggests that a widely prescribed class of diabetes drugs may be doing exactly that, potentially reframing how clinicians think about metabolic therapies in psychiatric populations.
Drawing on Veterans Affairs health data spanning 2016 to 2024, this target trial emulation study examined adults aged 65 and older diagnosed with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder who were initiating antidiabetic treatment. Researchers used marginal structural models with inverse probability weighting — a rigorous causal-inference approach — to compare dementia incidence between those who started SGLT2 inhibitors and those who did not. Both intention-to-treat and per-protocol analyses (the latter requiring at least three months of sustained use) were applied. Secondary outcomes included psychiatric emergency department visits and hospitalizations, adding a clinically meaningful dimension beyond cognitive endpoints alone.
SGLT2 inhibitors have accumulated a compelling portfolio of pleiotropic effects beyond glucose lowering — including mitochondrial biogenesis stimulation, neuroinflammation reduction, and AMPK pathway activation — all mechanisms increasingly implicated in neurodegeneration. Prior work has hinted at cardiovascular and renal benefits in diabetic populations, and emerging animal data suggest neuroprotective signaling. This study is notable for its focus on a high-risk psychiatric subgroup often excluded from clinical trials, using a sophisticated quasi-experimental design that approximates randomization. Key limitations include the predominantly male VA population, potential residual confounding from baseline metabolic burden, and reliance on ICD-coded dementia diagnoses rather than neuropsychological assessment. The findings are best interpreted as hypothesis-generating rather than definitive — but given the mechanistic plausibility and the unmet clinical need in this population, they represent a meaningful incremental advance warranting prospective validation.